Literature DB >> 31221781

Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma.

Grzegorz S Nowakowski1, Annalisa Chiappella2, Thomas E Witzig3, David W Scott4, Michele Spina5, Randy D Gascoyne3,4, Lei Zhang6, Jacqueline Russo6, Janet Kang6, Jingshan Zhang6, Yingyong Xu6, Umberto Vitolo2.   

Abstract

Mesh：

Year:  2020        PMID： 31221781      PMCID： PMC7012477          DOI： 10.3324/haematol.2019.220475

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

2.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.

Authors:  David W Scott; George W Wright; P Mickey Williams; Chih-Jian Lih; William Walsh; Elaine S Jaffe; Andreas Rosenwald; Elias Campo; Wing C Chan; Joseph M Connors; Erlend B Smeland; Anja Mottok; Rita M Braziel; German Ott; Jan Delabie; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Timothy C Greiner; Betty J Glinsmann-Gibson; Kai Fu; Louis M Staudt; Randy D Gascoyne; Lisa M Rimsza
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

Review 3.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

4.  Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

Authors:  Grzegorz S Nowakowski; Betsy LaPlant; William R Macon; Craig B Reeder; James M Foran; Garth D Nelson; Carrie A Thompson; Candido E Rivera; David J Inwards; Ivana N Micallef; Patrick B Johnston; Luis F Porrata; Stephen M Ansell; Randy D Gascoyne; Thomas M Habermann; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2014-08-18       Impact factor: 44.544

5.  The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries.

Authors:  Eisuke Shiozawa; Toshiko Yamochi-Onizuka; Masafumi Takimoto; Hidekazu Ota
Journal:  Leuk Res       Date:  2007-04-19       Impact factor: 3.156

6.  Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.

Authors:  David W Scott; Anja Mottok; Daisuke Ennishi; George W Wright; Pedro Farinha; Susana Ben-Neriah; Robert Kridel; Garrett S Barry; Christoffer Hother; Pau Abrisqueta; Merrill Boyle; Barbara Meissner; Adele Telenius; Kerry J Savage; Laurie H Sehn; Graham W Slack; Christian Steidl; Louis M Staudt; Joseph M Connors; Lisa M Rimsza; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

7.  Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.

Authors:  Umberto Vitolo; Annalisa Chiappella; Silvia Franceschetti; Angelo Michele Carella; Ileana Baldi; Giorgio Inghirami; Michele Spina; Vincenzo Pavone; Marco Ladetto; Anna Marina Liberati; Anna Lia Molinari; Pierluigi Zinzani; Flavia Salvi; Pier Paolo Fattori; Alfonso Zaccaria; Martin Dreyling; Barbara Botto; Alessia Castellino; Angela Congiu; Marcello Gaudiano; Manuela Zanni; Giovannino Ciccone; Gianluca Gaidano; Giuseppe Rossi
Journal:  Lancet Oncol       Date:  2014-05-13       Impact factor: 41.316

8.  Stromal gene signatures in large-B-cell lymphomas.

Authors:  G Lenz; G Wright; S S Dave; W Xiao; J Powell; H Zhao; W Xu; B Tan; N Goldschmidt; J Iqbal; J Vose; M Bast; K Fu; D D Weisenburger; T C Greiner; J O Armitage; A Kyle; L May; R D Gascoyne; J M Connors; G Troen; H Holte; S Kvaloy; D Dierickx; G Verhoef; J Delabie; E B Smeland; P Jares; A Martinez; A Lopez-Guillermo; E Montserrat; E Campo; R M Braziel; T P Miller; L M Rimsza; J R Cook; B Pohlman; J Sweetenham; R R Tubbs; R I Fisher; E Hartmann; A Rosenwald; G Ott; H-K Muller-Hermelink; D Wrench; T A Lister; E S Jaffe; W H Wilson; W C Chan; L M Staudt
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245

9.  Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.

Authors:  Nara Yoon; Soomin Ahn; Hae Yong Yoo; Suk Jin Kim; Won Seog Kim; Young Hyeh Ko
Journal:  Oncotarget       Date:  2017-03-28

10.  Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis.

Authors:  Xiaojuan Gao; Jia Li; Yaqi Wang; Shuai Liu; Baohong Yue
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240
View more
  4 in total

1.  A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.

Authors:  Zijun Y Xu-Monette; Hongwei Zhang; Feng Zhu; Alexandar Tzankov; Govind Bhagat; Carlo Visco; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Eric D Hsi; Hua You; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Benjamin M Parsons; J Han van Krieken; Miguel A Piris; Jane N Winter; Fredrick B Hagemeister; Babak Shahbaba; Ivan De Dios; Hong Zhang; Yong Li; Bing Xu; Maher Albitar; Ken H Young
Journal:  Blood Adv       Date:  2020-07-28

2.  Immunophenotypic Landscape and Prognosis of Diffuse Large B-Cell Lymphoma with MYC/BCL2 Double Expression: An Analysis of A Prospectively Immunoprofiled Cohort.

Authors:  Bogyeong Han; Sehui Kim; Jiwon Koh; Jeemin Yim; Cheol Lee; Dae Seog Heo; Tae Min Kim; Jin Ho Paik; Yoon Kyung Jeon
Journal:  Cancers (Basel)       Date:  2020-11-09       Impact factor: 6.639

3.  Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.

Authors:  Grzegorz S Nowakowski; Fangxin Hong; David W Scott; William R Macon; Rebecca L King; Thomas M Habermann; Nina Wagner-Johnston; Carla Casulo; James L Wade; Gauri G Nagargoje; C M Reynolds; Jonathon B Cohen; Nadia Khan; Jennifer E Amengual; Kristy L Richards; R F Little; John P Leonard; Jonathan W Friedberg; Lale Kostakoglu; Brad S Kahl; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2021-02-08       Impact factor: 50.717

4.  ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.

Authors:  Grzegorz S Nowakowski; Annalisa Chiappella; Randy D Gascoyne; David W Scott; Qingyuan Zhang; Wojciech Jurczak; Muhit Özcan; Xiaonan Hong; Jun Zhu; Jie Jin; David Belada; Juan Miguel Bergua; Francesco Piazza; Heidi Mócikova; Anna Lia Molinari; Dok Hyun Yoon; Federica Cavallo; Monica Tani; Kazuhito Yamamoto; Koji Izutsu; Koji Kato; Myron Czuczman; Sarah Hersey; Adrian Kilcoyne; Jacqueline Russo; Krista Hudak; Jingshan Zhang; Steve Wade; Thomas E Witzig; Umberto Vitolo
Journal:  J Clin Oncol       Date:  2021-02-23       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.